mosunetuzumab,Atezolizumab
roche
['leusm', 'mosunetuzumab', 'lymphoma', 'lymsm']
congress| #17icml reports outcomes of mosunetuzumab in patients with r/r fl post 2 or more lines of therapy. mosenutuzumab monotherapy demonstrated high efficacy with many remaining event-free 2 years after end of treatment #lymsm #leusm #lymphoma 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm